Skip to main content
. Author manuscript; available in PMC: 2012 Sep 25.
Published in final edited form as: Hepatology. 2010 Nov 9;52(6):2158–2166. doi: 10.1002/hep.23945

Figure 2. Mmp23b knockdown phenotype.

Figure 2

(A–B) WISH using a ceruloplasmin (cp) probe. (A) Control and mmp23b morphant (88%, n=25) embryos at 3dpf. Note the dramatically reduced liver in the mmp23b morpholino injected embryo (black arrow) compared with that in the control embryo. (B) Control and mmp23b morphant (91.7%, n=24) embryos at 5dpf. The liver in the morphant remains underdeveloped. (C) mmp23b:GFP expression at 3dpf. Note the severe reduction of GFP expression in the developing liver area in the mmp23b morphant (white arrow, 86.4%, n=22,). (D) WISH using a gata6 probe. Control embryo and mmp23b morphant at 3dpf. Note only the liver expression of gata6 is reduced (black arrow, 73.9%, n=23) whereas pancreatic and gut expression of gata6 remain unaffected. (E–F) WISH using a hhex probe. (E) Control and mmp23b morphant embryos (96.2%, n=26) at 36hpf. (F) Control and mmp23b morphant embryos (84%, n=25) at 48hpf. All embryos are mounted as dosal view with anterior to the left.